The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
63 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,141,777 in first-year total cost, median $193,324.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRLB-B (O1)]10
- Special Emphasis Panel[ZCA1 SRLB-1 (O1)]9
- Special Emphasis Panel[ZCA1 RPRB-7 (O1)]8
- Special Emphasis Panel[ZCA1 SRLB-2 (O1)]7
- Special Emphasis Panel[ZCA1 SRLB-C (O1)]7
Most frequent institutions
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE3
- DANA-FARBER CANCER INST2
- DUKE UNIVERSITY2
- JOHNS HOPKINS UNIVERSITY2
- OHIO STATE UNIVERSITY2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Small molecule Fzd7 inhibitors for cancer therapy1R21CA182056-01 | LI, YONGHE | SOUTHERN RESEARCH INSTITUTE, AL | $259,490 | ZCA1 |
| 2014 | Characterization and suppression of resistance to NEDD8 E1 inhibition1R21CA182178-01 | PETROSKI, MATTHEW | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $254,475 | ZCA1 |
| 2014 | Systems biology of glutamine utilization in melanoma1R21CA182209-01 | SMITH, JEFFREY W | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $254,475 | ZCA1 |
| 2014 | Functional landscape of Eph receptor mutations in melanoma1R21CA175881-01A1 | PASQUALE, ELENA B | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $254,475 | ZCA1 |
| 2014 | Prediction of Treatment-Related Mortality and Therapeutic Resistance in AML1R21CA182010-01 | OTHUS, MEGANWALTER, ROLAND BRUNO | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $234,219 | ZCA1 |
| 2014 | Mechanism of Notch-induced leukemogenesis in lymphocytes1R21CA176811-01A1 | WINANDY, SUSAN M | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $226,341 | ZCA1 |
| 2014 | Targeting tumor desmoplasia to harness cytotoxic immune responses1R21CA182598-01 | CREMASCO, VIVIANA | DANA-FARBER CANCER INST, MA | $222,850 | ZCA1 |
| 2014 | Development of a Genomic Expression Signature Associated with Chemoresistance1R21CA181617-01 | MARCHION, DOUGLAS C | H. LEE MOFFITT CANCER CTR & RES INST, FL | $219,893 | ZCA1 |
| 2014 | How p16 and MC1R mutations synergistically exacerbate melanoma risk.1R21CA183440-01 | ABDEL-MALEK, ZALFACASSIDY, PAMELA B.LEACHMAN, SANCY ANN | UNIVERSITY OF CINCINNATI, OH | $218,776 | ZCA1 |
| 2014 | Determine the role of TLR1 signaling in chronic inflammation and colorectal cance1R21CA182595-01 | DEPAOLO, R WILLIAM | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $214,727 | ZCA1 |
| 2014 | Determination of Musashi1/CD44v6 signaling in mesenchymal glioma stem cells1R21CA175875-01A1 | NAKANO, ICHIROPENALVA, LUIZ OTAVIO | OHIO STATE UNIVERSITY, OH | $211,494 | ZCA1 |
| 2014 | Enhancing Oncolytic Virotherapy with Type III Interferon1R21CA175802-01A1 | ROBEK, MICHAEL | YALE UNIVERSITY, CT | $211,431 | ZCA1 |
| 2014 | Characterizing Novel Interaction Partners of FMS-Like Tyrosine Kinase ( FLT3)1R21CA175667-01A1 | DUFFIELD, AMY SUSAN | JOHNS HOPKINS UNIVERSITY, MD | $211,410 | ZCA1 |
| 2014 | Effects of Message Framing and Risk Feedback on CRC Screening1R21CA181256-01 | LIPKUS, ISAAC M | DUKE UNIVERSITY, NC | $210,796 | ZCA1 |
| 2014 | Development and feasibility testing of a lung cancer screening decision aid1R21CA173880-01A1 | BYRNE, MARGARET MSTUDTS, JAMIE L | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $209,464 | ZCA1 |
| 2014 | Use of DND1 to counteract miRNA function in cancers1R21CA175833-01A1 | MATIN, ANGABIN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2014 | Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas1R21CA182020-01 | WEBER, MICHAEL J. | UNIVERSITY OF VIRGINIA, VA | $206,190 | ZCA1 |
| 2014 | A Novel Agent with Dual Functions to Treat Head and Neck Cancer1R21CA176032-01A1 | TOBACK, FREDERICK GARY | UNIVERSITY OF CHICAGO, IL | $206,190 | ZCA1 |
| 2014 | In Situ Synthesis Of GPCR Ligands1R21CA181784-01 | CHEREZOV, VADIMZHANG, QINGHAI | SCRIPPS RESEARCH INSTITUTE, THE, CA | $206,081 | ZCA1 |
| 2014 | Defining the Cellular Target of Radiation Therapy1R21CA175839-01A1 | KIRSCH, DAVID GUY | DUKE UNIVERSITY, NC | $204,885 | ZCA1 |
| 2014 | Functional effects of all possible point mutations in oncogenes1R21CA175664-01A1 | BOLON, DANIEL N | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $203,272 | ZCA1 |
| 2014 | Role of Ly6 genes in estrogen receptor positive and negative breast cancer1R21CA175862-01A1 | UPADHYAY, GEETA | GEORGETOWN UNIVERSITY, DC | $202,928 | ZCA1 |
| 2014 | Latent Dirichlet Allocation for Protein Inference in Quantitative Proteomics1R21CA181382-01 | COHEN, AARON M. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $200,970 | ZCA1 |
| 2014 | D-peptide activators of p53 as anticancer therapeutics1R21CA167296-01A1 | LU, WUYUAN | UNIVERSITY OF MARYLAND BALTIMORE, MD | $200,318 | ZCA1 |
| 2014 | High-dose Vitamin D Supplementation for ADT-induced Side Effects1R21CA175793-01A1 | PEPPONE, LUKE JOSEPH | UNIVERSITY OF ROCHESTER, NY | $200,318 | ZCA1 |
| 2014 | Mobile Application for Guided Imagery to Address Smoking, Diet and Physical Activ1R21CA174639-01A1 | GORDON, JUDITH SARAH | UNIVERSITY OF ARIZONA, AZ | $200,178 | ZCA1 |
| 2014 | Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors1R21CA175840-01A1 | COMPAS, BRUCE E | VANDERBILT UNIVERSITY, TN | $198,930 | ZCA1 |
| 2014 | PAGE4 as a Novel Target for Prostate Cancer Prevention1R21CA181730-01 | KULKARNI, PRAKASHORBAN, JOHN | UNIV OF MARYLAND, COLLEGE PARK, MD | $198,360 | ZCA1 |
| 2014 | Developing a Lung Cancer Screening Registry in a State with a High Smoking Rate1R21CA175983-01A1 | HENDERSON, LOUISE | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $198,360 | ZCA1 |
| 2014 | Sensitize leukemia cells to differentiation by inhibiting necroptosis signal1R21CA181970-01 | ZHANG, JIWANG | LOYOLA UNIVERSITY CHICAGO, IL | $197,055 | ZCA1 |
| 2014 | Prostate-targeted CRMP4 saRNA as anti-metastatic therapy1R21CA175279-01A1 | LI, BENYI | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $197,055 | ZCA1 |
| 2014 | Determination of the role of CHD5 tumor suppressor in the zebrafish model1R21CA182197-01 | OGAS, JOSEPH P | PURDUE UNIVERSITY, IN | $193,324 | ZCA1 |
| 2014 | FBX044 mediated BRCA1 degradation in sporadic breast cancers1R21CA182268-01 | HU, YANFEN | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $193,160 | ZCA1 |
| 2014 | PKM2 coordinates glycolysis and glutaminolysis in cancer cells1R21CA181914-01 | LIU, ZHI-REN | GEORGIA STATE UNIVERSITY, GA | $193,140 | ZCA1 |
| 2014 | The pathophysiology and palliation of the paclitaxel-induced acute pain syndrome1R21CA180997-01 | FIELDS, ALAN P.JATOI, AMINAH | MAYO CLINIC ROCHESTER, MN | $192,765 | ZCA1 |
| 2014 | Cellular and Biologic Origins of CLL1R21CA175912-01A1 | DAVIS, RANDALL S | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $191,835 | ZCA1 |
| 2014 | Prognostic potential of low-level mutations in meylodysplastic syndrome1R21CA175542-01A1 | MAKRIGIORGOS, G. MIKE | DANA-FARBER CANCER INST, MA | $190,313 | ZCA1 |
| 2014 | Characterization of non-competitive proteasome binding1R21CA182926-01 | REID, GAVIN EDMUNDTEPE, JETZE J. | MICHIGAN STATE UNIVERSITY, MI | $189,921 | ZCA1 |
| 2014 | Reducing Craving for Cancer-promoting Foods Via Cognitive Self-regulation1R21CA175241-01A1 | BERKMAN, ELLIOT TODD | UNIVERSITY OF OREGON, OR | $189,225 | ZCA1 |
| 2014 | Cancer treatment retraumatization in sexual abuse survivors1R21CA173163-01A1 | SCHNUR, JULIE B. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $184,331 | ZCA1 |
| 2014 | Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles1R21CA175618-01A1 | SACHDEVA, MANDIP SINGH | FLORIDA AGRICULTURAL AND MECHANICAL UNIV, FL | $182,126 | ZCA1 |
| 2014 | Culturing viably captured circulating tumor cells using conditional reprogramming1R21CA182050-01 | COTE, RICHARD JAMES | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $181,612 | ZCA1 |
| 2014 | Novel Treatment to Enhance Smoking Cessation before Cancer Surgery1R21CA181569-01 | TOLL, BENJAMIN ANDREW | YALE UNIVERSITY, CT | $181,069 | ZCA1 |
| 2014 | Radiobiology Investigations of Ions Heavier than Protons1R21CA182259-01 | HELD, KATHRYN DALE | MASSACHUSETTS GENERAL HOSPITAL, MA | $180,525 | ZCA1 |
| 2014 | Genetic Modifiers for Cancer Stem Cells in Secondary MDS/AML1R21CA159203-01A1 | COREY, SETH JOEL | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $177,197 | ZCA1 |
| 2014 | Structural Studies of the Tumor M2 Isoform of Pyruvate Kinase1R21CA181751-01 | BOWMAN, GREGORY DEANLEE, YOUNG-SAM | JOHNS HOPKINS UNIVERSITY, MD | $176,175 | ZCA1 |
| 2014 | Regulation of Macrophages by miRNA-155 in Colon Cancer: Benefits of Quercetin1R21CA175636-01A1 | MURPHY, ELIZABETH ANGELA | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $174,218 | ZCA1 |
| 2014 | Role of DAB2IP in Prostate Cancer Patients Treated with Radiation Therapy1R21CA175879-01A1 | SAHA, DEBABRATA | UT SOUTHWESTERN MEDICAL CENTER, TX | $172,913 | ZCA1 |
| 2014 | Pluripotent stem cells as a novel model to test hereditary cancer variants1R21CA181959-01 | HEINEN, CHRISTOPHER D. | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $170,449 | ZCA1 |
| 2014 | Targeting metabolism in leukemic stem cells1R21CA181754-01 | QU, CHENG-KUI | EMORY UNIVERSITY, GA | $169,650 | ZCA1 |
| 2014 | Src, p53 and estrogen receptor-positive breast cancer1R21CA177382-01A1 | COURTNEIDGE, SARA A | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $167,475 | ZCA1 |
| 2014 | Discovery of Homologous Recombination DNA Repair Deficiency in Lung Tumor1R21CA181291-01 | DUAN, WENRUI | OHIO STATE UNIVERSITY, OH | $167,204 | ZCA1 |
| 2014 | The role of b-catenin/Tcf-1 signaling in T-cell leukemia/lymphoma1R21CA175821-01A1 | GOUNARI, FOTINI | UNIVERSITY OF CHICAGO, IL | $166,981 | ZCA1 |
| 2014 | Early detection of breast cancer serum antigens with lambodies1R21CA181830-01 | MAO, LI | UNIVERSITY OF MARYLAND BALTIMORE, MD | $166,931 | ZCA1 |
| 2014 | REGULATING GENOME FIDELITY AND CANCER PROGRESSION1R21CA176249-01A1 | BAMBARA, ROBERT A | UNIVERSITY OF ROCHESTER, NY | $166,931 | ZCA1 |
| 2014 | DEVELOPMENT OF SITE-SPECIFIC SCFV CONJUGATES FOR CANCER IMAGING1R21CA181022-01 | ROGERS, BUCK E. | WASHINGTON UNIVERSITY, MO | $165,300 | ZCA1 |
| 2014 | Bayesian Integrative Clustering for Determining Molecular Based Cancer Subty1R21CA182715-01 | FRIDLEY, BROOKE L | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $164,213 | ZCA1 |
| 2014 | Comprehensive Identification of CDK8 Kinase Targets Using SILAC Phosphoproteomics1R21CA175448-01A1 | OLD, WILLIAM MARLAND | UNIVERSITY OF COLORADO, CO | $161,057 | ZCA1 |
| 2014 | Manipulation of macrophage Alu RNA metabolism by breast cancer cells1R21CA181920-01 | CHAUDHURI, GAUTAM | MEHARRY MEDICAL COLLEGE, TN | $158,231 | ZCA1 |
| 2014 | GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma1R21CA183445-01 | THOMAS-TIKHONENKO, ANDREI | CHILDREN'S HOSP OF PHILADELPHIA, PA | $146,160 | ZCA1 |
| 2014 | Reducing Lung Cancer Survivor Anxiety (RELAX) with Brief Device-Guided Breathing1R21CA182111-01 | DANHAUER, SUZANNE C | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $133,690 | ZCA1 |
| 2014 | TWO HIT GENE MAPPING IN RENAL CELL CARCINOMA1R21CA175979-01A1 | MCKAY, JAMES DOWLING | INTERNATIONAL AGENCY FOR RES ON CANCER | $126,247 | ZCA1 |
| 2014 | Targeting tumor cell Toll-like receptor1R21CA176698-01A1 | ZHANG, DEKAI | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX | $123,203 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.